Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$105,000.00

Safety and effectiveness of pharmacological and non-pharmacological treatments in older adults with dementia

FY 2016-17

Summary
As dementia progresses, patients can develop low mood, altered sleep and agitation, which are called behavioural and psychological symptoms of dementia (BPSD). Both medication- and non-medication-based (i.e. environmental modifications, support for caregivers) therapies can be used to treat these symptoms, but we don't know which of these are safest and most effective. This is important given that there are significant safety concerns associated with some commonly prescribed medications (i.e. increased risk of death) that are used to treat these symptoms. Furthermore, it is unclear whether the risk of death is even greater in patients with multiple chronic medical conditions (multimorbidity). Given the uncertainty surrounding these clinical questions, we will study (1) the comparative safety and effectiveness of medication- and non-medication-based therapies for the treatment of BPSD by using an evolving research methodology (network meta-analysis) to directly and indirectly compare these therapies using data from several types of studies (i.e. studies conducted for Health Canada drug approval, studies conducted once drugs were prescribed in the general population for the treatment of BPSD), (2) the clinical implications of using different statistical models to incorporate data for safety outcomes from randomized controlled trials (RCTs) and observational studies into the network meta-analysis from (1), and (3) the safety of antipsychotics (medication used to treat BPSD) in patients with dementia and multimorbidity to ascertain their risk of adverse outcomes (i.e. risk of death) using health administrative databases. Given the growing burden of dementia, this research is important because it will help to optimize patient care and it will directly inform decision making for patients, caregivers, policy-makers, and health care professionals to provide advice on which treatment is optimal.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365431
Name
Watt Jennifer A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Safety and effectiveness of pharmacological and non-pharmacological treatments in older adults with dementia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Behavioural And Psychological Symptoms Of Dementia (Bpsd); Cohort Study; Drug Effectiveness; Drug Efficacy; Drug Safety; Geriatrics; Meta-Analysis; Multimorbidity; Network Meta-Analysis; Systematic Review
Abstract
As dementia progresses, patients can develop low mood, altered sleep and agitation, which are called behavioural and psychological symptoms of dementia (BPSD). Both medication- and non-medication-based (i.e. environmental modifications, support for caregivers) therapies can be used to treat these symptoms, but we don't know which of these are safest and most effective. This is important given that there are significant safety concerns associated with some commonly prescribed medications (i.e. increased risk of death) that are used to treat these symptoms. Furthermore, it is unclear whether the risk of death is even greater in patients with multiple chronic medical conditions (multimorbidity). Given the uncertainty surrounding these clinical questions, we will study (1) the comparative safety and effectiveness of medication- and non-medication-based therapies for the treatment of BPSD by using an evolving research methodology (network meta-analysis) to directly and indirectly compare these therapies using data from several types of studies (i.e. studies conducted for Health Canada drug approval, studies conducted once drugs were prescribed in the general population for the treatment of BPSD), (2) the clinical implications of using different statistical models to incorporate data for safety outcomes from randomized controlled trials (RCTs) and observational studies into the network meta-analysis from (1), and (3) the safety of antipsychotics (medication used to treat BPSD) in patients with dementia and multimorbidity to ascertain their risk of adverse outcomes (i.e. risk of death) using health administrative databases. Given the growing burden of dementia, this research is important because it will help to optimize patient care and it will directly inform decision making for patients, caregivers, policy-makers, and health care professionals to provide advice on which treatment is optimal.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Watt, Jennifer A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~